 | | Vol. 12.35 – 17 September, 2021 |
| |
|
|
| Scientists provided the novel mechanistic model of ATF6 activation and endoplasmic reticulum (ER) stress implication in the progression of prostate cancer, suggesting ATF6 is a novel promising target for prostate cancer therapy.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators described the identification of A4B17, a small molecule that inhibits BAG1L– androgen receptor (AR) N-terminal domain (NTD) interaction, attenuated BAG1L-mediated AR NTD activity, downregulated AR target gene expression, and inhibited proliferation of AR-positive prostate cancer cells.
[ACS Chemical Biology] |
|
|
|
| Researchers confirmed the prostatic oncogene WT1, as a direct target of miR-642a-5p, and treatment of 22Rv1 and LNCaP prostate cancer cells with WT1 siRNA or a small molecule inhibitor of WT1 reduced cell proliferation.
[Scientific Reports] |
|
|
|
| To outline the inhibitory role of HIC on prostate cancer cells, PC-3 and DU145 cell lines were treated with the respective IC50 concentrations, which reduced cell proliferation, adherence properties and spheroid formation.
[Future Medicinal Chemistry] |
|
|
|
| Considering that exosomes are important components in communication between tumor cells and the microenvironment, researchers examined the angiogenic potential of exosomes released from prostate cancer cell lines with distinctive profiles of androgen response through exosomes isolation, microscopy and uptake, functional assays follow up by microarray, RT-qPCR and bioinformatics analysis.
[Cellular Signalling] |
|
|
|
| Scientists investigated the potential of using a marine triterpenoid saponin, holothurin A, on targeting androgen receptor expression of prostate cancer using in vitro and in silico studies.
[Journal of Biomolecular Structure and Dynamics] |
|
|
|
| The effects of interference with eIF5B expression on the growth, morphology, and immunity of the tumor, as well as PD-L1 expression in the tumor, were verified by tumor xenograft assays in vivo.
[BMC Cancer] |
|
|
|
| The authors found significantly increased levels of miR-182 in prostate cancer tissues compared to benign prostatic hyperplasia. Also, miR-182 showed increased expression in African Americans prostate cancer cell lines and tissue samples compared to European Americans.
[BMC Cancer] |
|
|
|
| The expression of N-Myc and TEM8 was detected in benign prostatic hyperplasia and prostate cancer tissues by immunohistochemistry.
[Medical Oncology] |
|
|
|
| CD133+ cells were sorted from prostate cancer cells using magnetic fluorescence cell sorting technology and were considered as cancer stem cells.
[Cell Biology International] |
|
|
|
| Scientists evaluated the effect of radiation on prostate cancer cells pretreated with leuprolide, alone or in combination with IN3, as radiosensitizers.
[International Journal of Radiation Biology] |
|
|
|
|
| Over the past two decades, multiple studies on the use of neoadjuvant treatment have been performed using conventional androgen deprivation therapy, which comprises luteinizing hormone-releasing hormone agonists or antagonists and/or first-line anti-androgens.
[Nature Reviews Urology] |
|
|
|
| The authors provide an overview of the current and emerging knowledge on non-genomic signaling with a focus on breast and prostate cancers and its clinical relevance.
[Molecular and Cellular Endocrinology] |
|
|
|
|
| Veracyte, Inc. announced that its Decipher® Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer.
[Veracyte, Inc. (BusinessWire, Inc.)] |
|
|
|
|
|
| October 19 – 20, 2021
Virtual |
|
|
|
|
|
| | Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| Zhejiang University School of Medicine – Hangzhou, China |
|
|
|
| | CRUK Beatson Institute for Cancer Research – Glasgow, Scotland, United Kingdom |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
